Pain‐Related Gene Solute Carrier Family 24 Member 3 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma: A Study via Integrated Bioinformatics Analyses and Experimental Verification

Abstract

The aim of this study was to explore cervical carcinoma and screen a suitable gene as the biomarker used for prognosis evaluation as well as pain therapy. Low expression levels of solute carrier family 24 member 3 (SLC24A3) was involved in the appearance and development of numerous malignancies. Nevertheless, the prognostic value of SLC24A3 expression with cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) patients remains uncertain. During the present study, SLC24A3 expression in CESC was retrieved from TCGA, GEO, and MSigDB databases. Based on TCGA and GEO profiles, we performed survival and difference analyses about SLC24A3 both in two GEO (GSE44001 and GSE63514) and TCGA-CESC cohorts (all p < 0.05 ), indicating that SLC24A3 was low expressed in tumors and associated with higher overall survival in CESC patients. Additionally, we programmed a series of analyses, including genomic profiling, enrichment analysis, immune infiltration analysis, and therapy-related analysis to identify the mechanism of the SLC24A3 in the process of cancer in CESC. Meanwhile, qRT-PCR was used to validate that the expression of SLC24A3 mRNA in Hela and SiHa cell lines was significantly lower than in PANC-1 and HUCEC cell lines. Our finding elucidated that the SLC24A3, a sodium-calcium regulator of cells, is an indispensable factor which can significantly influence the prognosis of patients with CESC and could provide novel clinical evidence to serve as a potential biological indicator for future diagnosis and pain therapy.

Acquisition and validation of four painful subtypes of colon adenocarcinoma and prognostic analysis

“…Adverse symptoms such as pain can be very burdensome for patients with colon adenocarcinoma and can have a very negative impact on the overall health-related quality of life (QoL) of patients with colon cancer [35] . Pain-related genes play an important role in the prognosis and pain-related effects of cancer patients, and low-expression of pain-related genes improves the survival of cancer patients [23] . This study is a correlation analysis of pain subtypes in COAD to suggest some solutions for COAD treatment.…”

“…Oncogenes have now been found to be associated with the development of cancer with pain [22] . The ndings on pain-related genes in cancer patients can provide a reference for the development of the target drugs for tumor therapy, which is of great signi cance for alleviating pain and improving the quality of life of cancer patients [23] . However, the research on pain subtypes in colon adenocarcinoma is lacking.…”